Compare RRC & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RRC | ROIV |
|---|---|---|
| Founded | 1976 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.1B | 21.0B |
| IPO Year | 1996 | 2021 |
| Metric | RRC | ROIV |
|---|---|---|
| Price | $36.43 | $31.14 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 18 | 9 |
| Target Price | ★ $43.67 | $28.94 |
| AVG Volume (30 Days) | 2.6M | ★ 5.6M |
| Earning Date | 04-21-2026 | 05-28-2026 |
| Dividend Yield | ★ 0.92% | N/A |
| EPS Growth | ★ 151.38 | N/A |
| EPS | ★ 1.44 | N/A |
| Revenue | ★ $3,115,515,000.00 | $8,260,000.00 |
| Revenue This Year | $15.60 | N/A |
| Revenue Next Year | $9.73 | $744.61 |
| P/E Ratio | $25.39 | ★ N/A |
| Revenue Growth | ★ 28.90 | N/A |
| 52 Week Low | $32.60 | $10.71 |
| 52 Week High | $48.31 | $32.79 |
| Indicator | RRC | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 31.37 | 60.76 |
| Support Level | $34.27 | $27.44 |
| Resistance Level | $36.61 | $32.79 |
| Average True Range (ATR) | 1.00 | 0.93 |
| MACD | -0.22 | 0.20 |
| Stochastic Oscillator | 6.44 | 75.99 |
Range Resources is an exploration and production firm whose operations represent a pure play in the Marcellus shale, located in the Appalachian region of Southwest Pennsylvania. The company went public as Lomak Petroleum in 1980 and later reorganized as Range Resources in 1998. After an expensive 10-year venture with a multi-basin strategy, Range Resources found its identity as an Appalachian natural gas producer, offloading its Permian assets in 2013. Range quickly became a leading US gas producer after its merger with Memorial Resource Development in 2016. Following the merger, Range saw its operational unit costs rise to an uncompetitive level and subsequently sold the assets in 2020 to return to its roots as an Appalachian producer.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.